Analyst firms · BofA Securities · YMAB
BofA Securities YMAB price target and rating history
Y-mAbs Therapeutics Inc. (YMAB) · Health Care
BofA Securities rates Y-mAbs Therapeutics Inc. (YMAB) Underperform with a $3 price target, as of its latest action on Apr 22, 2025. It has published 3 rating actions on YMAB since December 2022, including 0 upgrades and 3 downgrades.
- Current rating
- Underperform
- Price target
- $3
- Median target, all firms
- Too few
- Actions on YMAB
- 3
BofA Securities price target on YMAB
Every BofA Securities rating on YMAB
- Apr 22, 2025
- Dec 2, 2022
- Dec 2, 2022
Questions about BofA Securities and YMAB
- What is BofA Securities's price target for YMAB?
- BofA Securities's latest stated price target for Y-mAbs Therapeutics Inc. (YMAB) is $3, from its action on Apr 22, 2025.
- What is BofA Securities's rating on YMAB?
- BofA Securities rates YMAB Underperform, a bearish rating, as of Apr 22, 2025.
- When did BofA Securities last change its view on YMAB?
- On Apr 22, 2025, BofA Securities downgrades to Underperform from Neutral, price target $3.
More YMAB rating histories
All BofA Securities ratingsYMAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.